The DOI matches its Crossref record; 329 of the 329 references it cites were found in a registry or an index.
Neurotoxin-based models of Parkinson's disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–329 of 329
Transdermal nicotine in PD: A randomized, double-blind, placebo-controlled study
Vieregge, A., Sieberer, M. G., Jacobs, H., Hagenah, J., & Vieregge, P. (2001) · Neurology · doi:10.1212/wnl.57.6.1032 · Cited by 143
Muthane, U. B., Ramsay, K., Jiang, H., Jackson-Lewis, V. R., Donaldson, D. M., Fernando, S., Ferreira, M., & Przedborski, S. (1994) · Experimental Neurology · doi:10.1006/exnr.1994.1058 · Cited by 143
Proteasome inhibition and Parkinson's disease modeling
Bové, J., Zhou, C. H., Jackson-Lewis, V. R., Taylor, J. P., Chu, Y., Rideout, H. J., Wu, D.-C., Kordower, J. H., Petrucelli, L., & Przedborski, S. (2006) · Annals of Neurology · doi:10.1002/ana.20937 · Cited by 143
Self-citationHeikkila, R. E., & Cohen, G. (1972) · PubMed · Cited by 143
Manganese Superoxide Dismutase Overexpression Attenuates MPTP Toxicity
Klivenyi, P., St. Clair, D., Wermer, M., Yen, H.-C., Oberley, T., Yang, L., & Beal, M. F. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0191 · Cited by 142
Kirik, D., Georgievska, B., Bürger, C., Winkler, C., Muzyczka, N., Mandel, R. J., & Björklund, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062047599 · Cited by 142
Talpade, D. J., Greene, J. G., Higgins, D. S., & Greenamyre, J. T. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752611.x · Cited by 142
Karunakaran, S., Diwakar, L., Saeed, U., Agarwal, V., Ramakrishnan, S., Iyengar, S., & Ravindranath, V. (2007) · The FASEB Journal · doi:10.1096/fj.06-7580com · Cited by 141
Prediger, R. D., BATISTA, L., Medeiros, R., Pandolfo, P., Flório, J. C., & TAKAHASHI, R. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.07.001 · Cited by 141
Xu, K., Xu, Y.-H., Chen, J., & Schwarzschild, M. A. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.02.020 · Cited by 140
Mass fragmentography of dopamine and 6-hydroxydopamine
Curtius, H. ‐., Wolfensberger, M., Steinmann, B. U., Redweik, U., & Siegfried, J. (1974) · Journal of Chromatography A · doi:10.1016/s0021-9673(00)90882-3 · Cited by 138
Chiba, K., Peterson, L. A., Castagnoli, K., Trevor, A. J., & Castagnoli, N. (1985) · PubMed · Cited by 134
Effects of l ‐dopa and other amino acids against paraquat‐induced nigrostriatal degeneration
McCormack, A. L., & Monte, D. A. D. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01621.x · Cited by 131
Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys
Ovadia, A., Zhang, Z., & Gash, D. M. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)02012-8 · Cited by 131
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro
Rossetti, Z. L., Soroiut, A., Sharp, D. E., Hadjiconstantinou, M., & Neff, N. H. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90674-0 · Cited by 129
Paraquat Neurotoxicity Is Mediated by a Bak-dependent Mechanism
Fei, Q., McCormack, A. L., Monte, D. A. D., & Ethell, D. W. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m708451200 · Cited by 124
Harms, A. S., Barnum, C. J., Ruhn, K. A., Varghese, S., Treviño, I., Blesch, A., & Tansey, M. G. (2010) · Molecular Therapy · doi:10.1038/mt.2010.217 · Cited by 123
Andreassen, O. A., Ferrante, R. J., Dedeoglu, A., Albers, D. W., Klivènyi, P., Carlson, E. J., Epstein, C. J., & Beal, M. F. (2001) · Experimental Neurology · doi:10.1006/exnr.2000.7525 · Cited by 122
Rotenone inhibition of tubulin self-assembly
Marshall, L. E., & Himes, R. H. (1978) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(78)90315-x · Cited by 121
Jeon, B. S., Kholodilov, N. G., Oo, T. F., Kim, S., Tomaselli, K. J., Srinivasan, A. N., Stefanis, L., & Burke, R. E. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730322.x · Cited by 120
Cerebral damage in paraquat poisoning
Grant, H. C., Lantos, P. L., & Parkinson, M. C. (1980) · Histopathology · doi:10.1111/j.1365-2559.1980.tb02911.x · Cited by 119
Jenner, P. G. (2003) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(02)00115-3 · Cited by 119
Chronic high dose transdermal nicotine in Parkinson's disease: an open trial
Villafane, G., Césaro, P., Rialland, A., Baloul, S., Azimi, S., Bourdet, C., Houezec, J. L., Macquin‐Mavier, I., & Maison, P. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.01949.x · Cited by 118
l-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats
Alam, M., & Schmidt, W. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2003.12.021 · Cited by 118
Giovanni, A., Sonsalla, P. K., & Heikkila, R. E. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22504-6 · Cited by 117
Parain, K., Hapdey, C., Rousselet, E., Marchand, V., Dumery, B., & Hirsch, É. C. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03195-0 · Cited by 115
Rotenone inhibition of spindle microtubule assembly in mammalian cells
Brinkley, B. R., Barham, S. S., BARRANCO, S. C., & Fuller, G. M. (1974) · Experimental Cell Research · doi:10.1016/0014-4827(74)90210-9 · Cited by 115
The MPTP-treated primate as a model of motor complications in PD
Jenner, P. G. (2003) · Neurology · doi:10.1212/wnl.61.6_suppl_3.s4 · Cited by 111
Takeuchi, H., Yanagida, T., Inden, M., Takata, K., Kitamura, Y., Yamakawa, K., Sawada, H., Izumi, Y., Yamamoto, N., Kihara, T., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21869 · Cited by 111
Martí, M. J., James, C. J., Oo, T. F., Kelly, W. J., & Burke, R. E. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-06-02030.1997 · Cited by 110
Variable effects of chronic subcutaneous administration of rotenone on striatal histology
Zhu, C., Vourc’h, P., Fernagut, P., Fleming, S. M., Laćan, S., DiCarlo, C. D., Seaman, R. L., & Chesselet, M. (2004) · The Journal of Comparative Neurology · doi:10.1002/cne.20305 · Cited by 109
Attention and executive function deficits in chronic low‐dose MPTP‐treated non‐human primates
Decamp, E., & Schneider, J. S. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03586.x · Cited by 109
Boyce, S., Kelly, E., Reavill, C. A., Jenner, P. G., & MARSDEN, C. D. (1984) · Biochemical Pharmacology · doi:10.1016/0006-2952(84)90344-7 · Cited by 108
No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism
Halliday, G. M., Herrero, M. T., Murphy, K., McCann, H., Ros‐Bernal, F., Barcia, C., Mori, H., Blesa, F. J., & Obeso, J. A. (2009) · Movement Disorders · doi:10.1002/mds.22481 · Cited by 108
Toxicokinetics and toxicodynamics of paraquat accumulation in mouse brain
Prasad, K., Tarasewicz, E., Mathew, J., Ohman‐Strickland, P., Buckley, B., Richardson, J. R., & Richfield, E. K. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.11.003 · Cited by 107
Lemay, S., Chouinard, S., Blanchet, P. J., Masson, H., Soland, V., Beuter, A. C., & Bédard, M. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00172-6 · Cited by 107
Hantraye, P., Varastet, M., Peschanski, M., RICHE, D., Césaro, P., Jc, W., & Mazière, M. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90295-q · Cited by 107
Developing a stable bilateral model of parkinsonism in rhesus monkeys
Smith, R. D., Zhang, Z., Kurlan, R., McDermott, M., & Gash, D. M. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90176-g · Cited by 104
KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse
Pierri, M., Vaudano, E., Sager, T. N., & Englund, U. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.11.009 · Cited by 103
Przedborski, S., Jackson-Lewis, V. R., Kostić, V., Carlson, E. J., Epstein, C. J., & Cadet, J. L. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb10051.x · Cited by 102
Pérez‐Otaño, I., Herrero, M. T., Oset, C., CEBALLOS, M. L. D., Luquín, M. R., Obeso, J. A., & del Rı́o, J. A. (1991) · Brain Research · doi:10.1016/0006-8993(91)91444-6 · Cited by 98
Huang, L. Z., Parameswaran, N., Bordia, T., McIntosh, J. M., & Quik, M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06011.x · Cited by 98
Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model
Tapias, V., Cannon, J. R., & Greenamyre, J. T. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22201 · Cited by 97
Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease
Broom, L., Marinova-Mutafchieva, L., Sadeghian, M., Davis, J. B., Medhurst, A. D., & Dexter, D. T. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.12.026 · Cited by 96
Staal, R. G. W., & Sonsalla, P. K. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39240-7 · Cited by 96
Meissner, W. G., Prunier, C., Guilloteau, D., Chalon, S., Gross, C. E., & Bézard, E. (2003) · Molecular Neurobiology · doi:10.1385/mn:28:3:209 · Cited by 96
Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism
Snow, B. J. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.3.313 · Cited by 93
Jakowec, M. W., & Petzinger, G. M. (2004) · PubMed · Cited by 92
Attenuation of 6‐OHDA‐induced neurotoxicity in glutathione peroxidase transgenic mice
Bensadoun, J., Mirochnitchenko, O. V., Inouye, M., Aebischer, P., & Zurn, A. D. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00345.x · Cited by 92
Ebersbach, G., St�ck, M., M�ller, J., Wenning, G. K., Wissel, J., & Poewe, W. H. (1999) · Movement Disorders · Cited by 90
Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration
Kachroo, A., Irizarry, M. C., & Schwarzschild, M. A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.02.007 · Cited by 88
Asanuma, M., Hirata, H., & Cadet, J. L. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00665-9 · Cited by 88
Sarre, S., Yuan, H., Jonkers, N., Hemelrijck, A. V., Ebinger, G., & Michotte, Y. M. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02471.x · Cited by 87
Modelling Parkinson‐like neurodegeneration via osmotic minipump delivery of MPTP and probenecid
Alvarez‐Fischer, D., Guerreiro, S., Hunot, S., Saurini, F., Marien, M. R., Sokoloff, P., Hirsch, É. C., Hartmann, A., & Michel, P. P. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05651.x · Cited by 87
Paraquat: The Red Herring of Parkinson's Disease Research
Miller, G. W. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm223 · Cited by 87
Richter, F., Hamann, M., & Richter, A. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.21159 · Cited by 86
c-Jun mediates axotomy-induced dopamine neuron death in vivo
Crocker, S. J., Lamba, W. R., Smith, P. D., Callaghan, S. M., Slack, R. S., Anisman, H., & Park, D. S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231177098 · Cited by 85
Crocker, S. J., Wigle, N., Liston, P., Thompson, C. S., Lee, C. J., Xu, D., Roy, S., Nicholson, D. W., Park, D. S., MacKenzie, A., et al. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01653.x · Cited by 85
Hughes, J. T. (1988) · PubMed · Cited by 85
Peng, J., Stevenson, F. F., Oo, M. L., & Andersen, J. K. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.10.045 · Cited by 84
Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats
Aguiar, L. M. V., Júnior, H. V. N., Macêdo, D. S., Oliveira, A. A., de Freitas, R. M., Vasconcelos, S. M. M., Cunha, G. M. A., de Sousa, F. C. F., & Viana, G. S. D. B. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.05.027 · Cited by 82
Ries, V., Silva, R. M., Oo, T. F., Cheng, H., Rzhetskaya, M., Kholodilov, N. G., Flavell, R. A., Kuan, C.-Y., RAKIC, P. T., & Burke, R. E. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05713.x · Cited by 82
Taylor, J. R., Elsworth, J. D., Roth, R. H., Sladek, J. R., & Redmond, D. E. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00214-5 · Cited by 82
Novel investigational adenosine A2Areceptor antagonists for Parkinson's disease
Pinna, A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903241615 · Cited by 81
Mechanisms of rotenone-induced proteasome inhibition
Chou, A. P., Li, S., Fitzmaurice, A. G., & Bronstein, J. M. (2010) · NeuroToxicology · doi:10.1016/j.neuro.2010.04.006 · Cited by 80
Neuropsychiatric Behaviors in the MPTP Marmoset Model of Parkinson’s Disease
Fox, S. H., Visanji, N. P., Reyes, G., Huot, P., Gómez-Ramírez, J., Johnston, T. H., & Brotchie, J. M. (2010) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100009707 · Cited by 78
Blume, S. R., Cass, D. K., & Tseng, K. Y. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.05.017 · Cited by 76
Kopin, I. J. (1987) · Environmental Health Perspectives · doi:10.1289/ehp.877545 · Cited by 76
Lysosomal membrane permeabilization in Parkinson disease
Vila, M., Bové, J., Dehay, B., Rodríguez‐Muela, N., & Boya, P. (2010) · Autophagy · doi:10.4161/auto.7.1.13933 · Cited by 75
Self-citationGhosh, B., Antonio, T., Reith, M. E. A., & Dutta, A. K. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901618d · Cited by 75
Iravani, M. M., Syed, E. C. J., Jackson, M. J., Johnston, L. C., Smith, L. A., & Jenner, P. G. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03915.x · Cited by 75
Russ, H., Mihatsch, W., Gerlach, M., Riederer, P. F., & Przuntek, H. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90171-o · Cited by 72
Striatal 6-hydroxydopamine induces apoptosis of nigral neurons in the adult rat
Martí, M. J., Saura, J., Burke, R. E., Jackson-Lewis, V. R., Jiménez, A., Bonastre, M., & Tolosa, E. S. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03694-6 · Cited by 72
Mori, A., Ohashi, S., Nakai, M., Moriizumi, T., & Mitsumoto, Y. (2005) · Neuroscience Research · doi:10.1016/j.neures.2004.11.008 · Cited by 71
Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain.
Riachi, N. J., LaManna, J. C., & Harik, S. I. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23492-9 · Cited by 70
Joghataei, M. T., Roghani, M., Negahdar, F., & Hashemi, L. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.06.004 · Cited by 69
Paraquat Poisoning by Skin Absorption: A Review
Smith, J. (1988) · Human Toxicology · doi:10.1177/096032718800700103 · Cited by 67
Glia cell number modulates sensitivity to MPTP in mice
Smeyne, M., Jiao, Y., Shepherd, K. R., & Smeyne, R. J. (2005) · Glia · doi:10.1002/glia.20233 · Cited by 67
Koprich, J. B., Fox, S. H., Johnston, T. H., Goodman, A., Bourdonnec, B. L., Dolle, R. E., DeHaven, R. N., DeHaven‐Hudkins, D. L., Little, P., & Brotchie, J. M. (2011) · Movement Disorders · doi:10.1002/mds.23631 · Cited by 66
Hansard, M. J., Smith, L. A., Jackson, M. J., Cheetham, S. C., & Jenner, P. G. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039743 · Cited by 66
Saura, J., Parés, M., Bové, J., Pezzi, S., Alberch, J., Marín, C., TOLOSA, E. S., & Martí, M. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01676.x · Cited by 65
Self-citationArthur, C. R., Morton, S. L., Dunham, L. D., Keeney, P. M., & Bennett, J. P. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-37 · Cited by 65
Todd, R. D., Carl, J. L., Harmon, S. K., O’Malley, K. L., & Perlmutter, J. S. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-23-07776.1996 · Cited by 64
Rolland, A., Tandé, D., Herrero, M. T., Luquín, M. R., Vázquez‐Claverie, M., Karachi, C., Hirsch, É. C., & François, C. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06220.x · Cited by 62
Bézard, E., Ravenscroft, P., Gross, C. E., Crossman, A. R., & Brotchie, J. M. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0375 · Cited by 62
Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms
Blanchet, P. J., Calon, F., Morissette, M., Tahar, A. H., Bélanger, N., Samadi, P., Grondin, R., Grégoire, L., Meltzer, L. T., Paolo, T. D., et al. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.02.011 · Cited by 62
Peng, J., Oo, M. L., & Andersen, J. K. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07036.x · Cited by 60
Enhancement of audiogenic seizure by 6-hydroxydopamine
Bourn, W. M., Chin, L., & Picchioni, A. L. (1972) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1972.tb08916.x · Cited by 59
The Rotenone model of Parkinsonism — the five years inspection
Höglinger, G. U., Oertel, W. H., & Hirsch, É. C. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_41 · Cited by 57
JANSON, A. M., FUXE, K., SUNDSTRÖM, E., AGNATI, L. F., & GOLDSTEIN, M. (1988) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1988.tb08372.x · Cited by 56
Hutter-Saunders, J. A. L., Gendelman, H. E., & Mosley, R. L. (2011) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9269-4 · Cited by 56
Crocker, C. E., Khan, S., Cameron, M. D., Robertson, H. A., Robertson, G. S., & LoGrasso, P. V. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn1001107 · Cited by 56
Khwaja, M., McCormack, A., McIntosh, J. M., Di Monte, D. A., & Quik, M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04177.x · Cited by 54
Prediger, R. D., Rial, D., Medeiros, R., Figueiredo, C. P., Doty, R. L., & Takahashi, R. N. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.03885.x · Cited by 54
Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice
Rojo, A. I., Montero, C., Salazar‐Roa, M., Close, R. M., Fernández‐Ruíz, J., Sánchez-González, M. Á., de Sagarra, M. R., Jackson-Lewis, V. R., Cavada, C., & Cuadrado, A. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05060.x · Cited by 54
Rose, S., Croft, N. R., & Jenner, P. (2007) · Brain Research · doi:10.1016/j.brainres.2006.10.038 · Cited by 53
Mladenović, A., Perović, M., Zogovic, N. S., Kanazir, S., Rakić, L., & Ruždijić, S. (2003) · Brain Research · doi:10.1016/j.brainres.2003.10.035 · Cited by 53
Davey, G. P., Tipton, K. F., & Murphy, M. P. (1992) · Biochemical Journal · doi:10.1042/bj2880439 · Cited by 52
Inden, M., Kitamura, Y., Tamaki, A., Yanagida, T., Shibaike, T., Yamamoto, A., Takata, K., Yasui, H., Taira, T., Ariga, H., et al. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.07.009 · Cited by 52
Hauser, R. A., Salin, L., Juhel, N., & Konyago, V. L. (2006) · Movement Disorders · doi:10.1002/mds.21258 · Cited by 52
Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF
Emborg, M. E., Moirano, J. M., Raschke, J., Bondarenko, V., Zufferey, R., Peng, S. C., Ebert, A. D., Joers, V. L., Roitberg, B. Z., Holden, J. E., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.022 · Cited by 49
Interaction between 6-Hydroxydopamine and Transferrin: “Let My Iron Go”
Borisenko, G. G., Kagan, V. E., Hsia, C. J. C., & Schor, N. F. (2000) · Biochemistry · doi:10.1021/bi992296v · Cited by 48
Two new test methods to quantify motor deficits in a marmoset model for Parkinson's disease
Verhave, P. S., Vanwersch, R. A. P., van Helden, H. P. M., Smit, A. B., & Philippens, I. H. C. H. M. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.01.022 · Cited by 47
Caspase inhibition protects nigral neurons against 6-OHDA-induced retrograde degeneration
Cutillas, B., Espejo, M., Gil, J., Ferrer, I., & Ambrosio, S. (1999) · Neuroreport · doi:10.1097/00001756-199908200-00030 · Cited by 46
Pessiglione, M., Guehl, D., Hirsch, É. C., Féger, J., & Tremblay, L. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2003.03088.x · Cited by 46
Visanji, N. P., O’Neill, M. J., & Duty, S. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.04.015 · Cited by 45
Age and Parkinson’s Disease-Related Neuronal Death in the Substantia Nigra Pars Compacta
Eriksen, N., Stark, A. K., & Pakkenberg, B. (2009) · Springer eBooks · doi:10.1007/978-3-211-92660-4_16 · Cited by 44
Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model
Decamp, E., & Schneider, J. S. (2009) · Brain Research · doi:10.1016/j.brainres.2009.01.028 · Cited by 44
Adenosine A2A antagonism reverses levodopa‐induced motor alterations in hemiparkinsonian rats
Bové, J., Marín, C., Bonastre, M., & TOLOSA, E. S. (2002) · Synapse · doi:10.1002/syn.10112 · Cited by 43
Self-citationCoffee, caffeine‐related genes, and Parkinson's disease: A case–control study
Facheris, M., Schneider, N. K., Lesnick, T. G., de Andrade, M., Cunningham, J. M., Rocca, W. A., & Maraganore, D. M. (2008) · Movement Disorders · doi:10.1002/mds.22247 · Cited by 41
Johnston, T. H., Huot, P., Fox, S. H., WAKEFIELD, J. D., Sykes, K. A., Bartolini, W. P., Milne, G. T., Pearson, J. P., & Brotchie, J. M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.169532 · Cited by 40
Pessiglione, M., Guehl, D., Jan, C., François, C., Hirsch, É. C., Féger, J., & Tremblay, L. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2003.03089.x · Cited by 40
Protective Effect of Talipexole on MPTP-Treated Planarian, a Unique Parkinsonian Worm Model
Yoshihisa, K., Kakimura, J., & Takashi, T. (1998) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.78.23 · Cited by 38
Caffeine and Progression of Parkinson Disease
Simon, D. K., Swearingen, C. J., Hauser, R. A., Trugman, J. M., Aminoff, M. J., Singer, C., Truong, D. D., & Tilley, B. C. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31815a3f03 · Cited by 38
Oiwa, Y., Sánchez‐Pernaute, R., Harvey-White, J. D., & Bankiewicz, K. S. (2003) · Journal of neurosurgery · doi:10.3171/jns.2003.98.1.0136 · Cited by 36
Bové, J., Serrats, J., Mengod, G., Cortés, R., TOLOSA, E. S., & Marín, C. (2005) · Experimental Brain Research · doi:10.1007/s00221-005-2302-1 · Cited by 35
Self-citationRodent models of treatment-induced motor complications in Parkinson's disease
Cenci, M. A., & Ohlin, K. E. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70828-4 · Cited by 34
Cotzias, G. C., Papavasiliou, P. S., & Gellene, R. A. (1968) · Neurology · doi:10.1212/wnl.18.3.276 · Cited by 33
Caneda-Ferrón, B., Girolamo, L. A. D., Costa, T. C. S., Beck, K. E., Layfield, R., & Billett, E. E. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05130.x · Cited by 32
Hanrott, K., Murray, T. K., Orfali, Z., Ward, M., Finlay, C. J., O’Neill, M. J., & Wonnacott, S. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06097.x · Cited by 32
Ebert, A. D., Hann, H. J., & Bohn, M. C. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21480 · Cited by 29
Jungnickel, J., Kalve, I., Reimers, L., Nobre, A., Wesemann, M., Ratzka, A., Halfer, N., Lindemann, C., Schwabe, K., Töllner, K., et al. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.07.023 · Cited by 29
The Protective Effects of PBN Against MPTP Toxicity Are Independent of Hydroxyl Radical Trapping
Ferger, B., Teismann, P., Earl, C. D., Kuschinsky, K., & Oertel, W. H. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(99)00229-4 · Cited by 28
Tayarani‐Binazir, K. A., Jackson, M. J., Rose, S., McCreary, A. C., & Jenner, P. G. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.09.007 · Cited by 28
Itti, E., Villafane, G., Malek, Z., Brugières, P., Capacchione, D., Itti, L., Maison, P., Césaro, P., & Meignan, M. A. (2009) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32832cc204 · Cited by 27
Johnston, L. C., Jackson, M. J., Rose, S., McCreary, A. C., & Jenner, P. G. (2010) · Movement Disorders · doi:10.1002/mds.23249 · Cited by 17
Jackson, M., Andree, T., Hansard, M. J., Hoffman, D., Hurtt, M., Kehne, J., Pitler, T. A., Smith, L. A., Stack, G., & Jenner, P. (2009) · Journal of neural transmission · doi:10.1007/s00702-009-0323-9 · Cited by 15
Garrido‐Gil, P., Belzunegui, S., Sebastián, W. S., Izal‐Azcárate, A., López, B., Marcilla, I., & Luquín, M. R. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21845 · Cited by 14
Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1
Cited by
Rodent models in neuroscience research: is it a rat race?
Ellenbroek, B., & Youn, J. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.026120 · Cited by 627
Val-Laillet, D., Aarts, E., Weber, B., Ferrari, M., Quaresima, V., Stoeckel, L. E., Alonso-Alonso, M., Audette, M., Malbert, C. H., & Stice, E. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.03.016 · Cited by 442
Nava Catorce, M., & Gevorkian, G. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151204122017 · Cited by 356
The Role of Innate and Adaptive Immunity in Parkinson's Disease
Kannarkat, G. T., Boss, J. M., & Tansey, M. G. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130250 · Cited by 324
“MPP+ inhibits cellular respiration by direct inhibition of the mitochondrial transport chain leading to neuronal injury and death [12].”
BackgroundAlpha-synuclein and tau: teammates in neurodegeneration?
Moussaud, S., Jones, D. R., Moussaud-Lamodière, E. L., Delenclos, M., Ross, O. A., & McLean, P. J. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-43 · Cited by 287
Metadata
- Authors
- Bové, J., & Perier, C.
- Venue
- Neuroscience
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 211
- Pages
- 51-76
- ISSN
- 0306-4522 (ISSN-L)
- OpenAlex
- W2088318694
- Cited by
- 506
- References
- 329
- FWCI
- 17.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.